Literature DB >> 3557026

A comparison between peroral choledochoscopy and endoscopic retrograde cholangiopancreatography.

S Bar-Meir, S Rotmensch.   

Abstract

Nonoperative direct examination of the pancreaticobiliary system with an ultrathin fiberoptic endoscope was compared to endoscopic retrograde cholangiopancreatography (ERCP). Thirty-one patients were examined by both techniques. Direct examination of the biliary system was successful in 12 patients, seven of whom had had previous endoscopic sphincterotomy. In two patients it revealed stones missed on ERCP. In none of the patients was an examination of the pancreatic duct possible. ERCP visualized the biliary system in 28 patients and the pancreatic duct in 30 patients. In one patient the ERCP revealed a stone missed by the peroral choledochoscopy. Peroral choledochoscopy is complementary to ERCP and should be reserved for patients with probable pathology of the biliary tract and normal ERCP.

Entities:  

Mesh:

Year:  1987        PMID: 3557026     DOI: 10.1016/s0016-5107(87)71476-x

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  3 in total

1.  A new peroral mother-baby endoscope system for biliary tract disorders.

Authors:  Christian Prinz; Andreas Weber; Stefanie Goecke; Bruno Neu; Alexander Meining; Eckart Frimberger
Journal:  World J Gastrointest Endosc       Date:  2014-01-16

Review 2.  Per oral cholangiopancreatoscopy in pancreatico biliary diseases--expert consensus statements.

Authors:  Mohan Ramchandani; Duvvur Nageshwar Reddy; Sundeep Lakhtakia; Manu Tandan; Amit Maydeo; Thoguluva Seshadri Chandrashekhar; Ajay Kumar; Randhir Sud; Rungsun Rerknimitr; Dadang Makmun; Christopher Khor
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

3.  Management of pancreaticobiliary disease using a new intra-ductal endoscope: the Texas experience.

Authors:  Douglas S Fishman; Paul R Tarnasky; Sandeep N Patel; Isaac Raijman
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.